A phase II study of 4SC-202 in combination with checkpoint inhibitors in pre-treated patients with microsatellite-stable gastrointestinal cancers
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Avelumab (Primary) ; Domatinostat (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- Acronyms EMERGE
- 09 Aug 2018 According to a 4SC media release, the company expects safety data in Q1 2019 and early efficacy data in H2 2019.
- 26 Apr 2018 According to a 4SC media release, the company is expecting to initiate this study in the H1 2018.
- 21 Mar 2018 According to a 4SC media release, safety data is expected in 2H 2018 and top-line results in H2 2019.